Severe depression, suicide attempts, and ideation during the use of interferon beta by patients with multiple sclerosis

Clin Neuropharmacol. 2010 Nov-Dec;33(6):312-6. doi: 10.1097/WNF.0b013e3181f8d513.

Abstract

Background: Interferon (IFN) beta is a safe and efficient drug for treating multiple sclerosis (MS). It is widely accepted that previously depressed patients may get worse when using IFN-beta. There are few reports on the association of IFN-beta and severe depression among patients without previous psychiatric history.

Methods: Discussion of a case of a patient with MS who developed severe depression and attempted suicide while using IFN-beta encouraged us to review the subject. A group of neurologists in Brazil retrospectively gathered together their similar cases for the present paper.

Results: The present paper reports on 11 cases of severe depression with suicide attempts or ideation among patients with MS who were using IFN-beta. These patients had no previous history of any psychiatric disease. Nine patients developed the symptoms over a relatively short period (4 months, on average). Two patients developed severe depression after more than 1 year of treatment with IFN-beta. Phobic, aggressive, behavioral, psychotic, and manic symptoms also were observed in these patients, thus suggesting the existence of a complex mood-behavior disorder associated with this drug. Interferon beta withdrawal led to complete remission of symptoms. The Naranjo algorithm established a highly probable association between IFN-beta and this adverse reaction in these patients.

Conclusions: Although uncommon, severe depression with suicide ideation or attempts may be observed during treatment of MS with IFN-beta. This association should not discourage the use of this drug, but physicians need to be aware of this possible adverse event from IFN-beta.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Brazil / epidemiology
  • Depressive Disorder / chemically induced*
  • Depressive Disorder / complications
  • Depressive Disorder / epidemiology
  • Drug Monitoring
  • Female
  • Humans
  • Interferon Type I / adverse effects*
  • Interferon Type I / therapeutic use*
  • Male
  • Middle Aged
  • Mood Disorders / chemically induced
  • Mood Disorders / complications
  • Mood Disorders / epidemiology
  • Multiple Sclerosis / complications
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / psychology*
  • Prevalence
  • Recombinant Proteins
  • Suicidal Ideation*
  • Suicide, Attempted*
  • Treatment Outcome
  • Young Adult

Substances

  • Interferon Type I
  • Recombinant Proteins